T細胞白血病(T-Cell Leukemia)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
T-Cell Leukemia Overview 8
Therapeutics Development 9
Pipeline Products for T-Cell Leukemia – Overview 9
Pipeline Products for T-Cell Leukemia – Comparative Analysis 10
T-Cell Leukemia – Therapeutics under Development by Companies 11
T-Cell Leukemia – Therapeutics under Investigation by Universities/Institutes 12
T-Cell Leukemia – Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
T-Cell Leukemia – Products under Development by Companies 15
T-Cell Leukemia – Products under Investigation by Universities/Institutes 16
T-Cell Leukemia – Companies Involved in Therapeutics Development 17
Applied Immune Technologies Ltd 17
Astellas Pharma Inc. 18
Bristol-Myers Squibb Company 19
Celgene Corporation 20
iDD biotech SAS 21
Kyowa Hakko Kirin Co., Ltd. 22
MediGene AG 23
Nippon Kayaku Co., Ltd. 24
Pfizer Inc. 25
Pharmacyclics, Inc. 26
Sanofi 27
Stemline Therapeutics, Inc. 28
Theravectys S.A. 29
Tolero Pharmaceuticals, Inc. 30
T-Cell Leukemia – Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
AGS-67E – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
alemtuzumab – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Antibody to Inhibit HLA-A2 for Neurology, Infectious Diseases and T-Cell Leukemia – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
BMS-906024 – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Cell Therapy to Target CD38 for cancer – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
IDD-003 – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
INA-01 – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
lenalidomide – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
MMIG-202 – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
mogamulizumab – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Monoclonal Antibodies to Antagonize TCR for Leukemia and Autoimmune Disease – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Monoclonal Antibody to Target CCR9 for T Lymphoblastic Leukemia – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
NK-314 – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Oncolytic Virus to Target Glycoprotein gp160 for T-cell Leukemia – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
PCI-34051 – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
PF-03084014 – Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
SL-101 – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Synthetic Peptide for Oncology and Male health – Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
THV-02 – Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
TP-0903 – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
T-Cell Leukemia – Recent Pipeline Updates 68
T-Cell Leukemia – Dormant Projects 85
T-Cell Leukemia – Discontinued Products 86
T-Cell Leukemia – Product Development Milestones 87
Featured News & Press Releases 87
Feb 04, 2015: THERAVECTYS Obtains Orphan Drug Designation from the European Medicines Agency for Its Lentiviral Vector-Based Therapeutic Vaccine against Adult T-Cell Leukemia and Lymphoma 87
Dec 18, 2014: Approval for Additional Indication for Chemotherapy-Native CCR4-positive ATL of Mogamulizumab 88
Sep 29, 2014: Pfizer And Kyowa Hakko Kirin To Collaborate On Immuno-Oncology Combination Study 88
Aug 23, 2012: Kyowa Hakko Kirin Initiates Pivotal Phase II Trial Of Mogamulizumab In Patients With Adult T-cell Leukemia-Lymphoma In US And Europe 89
Jul 19, 2012: Application Seeking Approval for Additional Indication for ATL, PTCL and CTCL of Mogamulizumab 89
May 29, 2012: Kyowa Hakko Kirin Launches POTELIGEO Injection In Japan 90
Jan 25, 2012: Study Shows Leukemia Drug Kills Cancerous T-cells While Sparing Normal Immunity 90
Dec 07, 2010: Kyowa Hakko Kirin Announces Results From Japan Phase II Clinical Trial Of KW-0761 In Adult T-Cell Leukemia-Lymphoma 91
Appendix 92
Methodology 92
Coverage 92
Secondary Research 92
Primary Research 92
Expert Panel Validation 92
Contact Us 92
Disclaimer 93